DDJ Patient Article · As of March 2026 · Explained Simply
What Risks of HPV and Other Oral Viruses for Oral Cancer Are Really Proven, and Where Does a Signal Quickly Become an Overblown Threat Narrative?
Explained clearly based on current scientific studies. This article helps you make informed decisions with your dentist.
This article looks at a substance or influence and what research says about its possible effects.
Quick and Clear
The most important findings at a glance:
- There are indications of an association, but not yet definitive certainty.
- The scientific basis is good. Several high-quality studies arrive at similar results.
- It is important to separate diagnostics from risk.
- When it comes to viral risk signals, anatomical precision is often more important than maximum alarmism.
Why is this topic important for you?
You may have heard that there are differing opinions on this topic. This is because science is often more complex than a simple yes or no answer suggests. In this article, we explain what current research actually shows—without technical jargon and without omitting important details.
The topic requires a clear separation between virus detection, tumor presence, and clinically reliable risk assessment.
Why is this important for you? Because as a patient, you can make better decisions when you understand the background. This article does not replace a discussion with your dentist, but it gives you the knowledge to ask the right questions.
In research, the most important questions revolve around the following areas: virus detection vs. clinical endpoint, tumor localization and transmissibility, prevention, and education. In the following sections, we will explain what the studies say about each of these areas and what that means for your daily life.
What matters more: Virus detection or clinical endpoint?
A common patient question is how to weigh virus detection vs. clinical endpoint. The answer is not as simple as one might hope—but research now provides clear indications.
The question of whether a positive HPV detection in the oral cavity is equivalent to an oncologically relevant risk belongs to the most methodologically demanding differentiations in oral oncology. The available scientific evidence is based on several systematic reviews and summaries of multiple studies that pool data from over 100 individual studies involving several thousand patients. Katirachi et al. (2023), in their summary of multiple studies, included 31 studies with a total of 5,007 patients from 24 countries and determined a pooled HPV positivity rate in oral squamous cell carcinoma (OSCC) of only 6%. Only one of the included studies found a statistically significant association between HPV and OSCC. The authors concluded that HPV may not be a necessary or strong risk factor in OSCC oncogenesis. Fonsêca et al. (2023) confirmed this magnitude in an independent summary of multiple studies from 65 studies, reporting a pooled HPV prevalence of 10% in the oral cavity compared to 42% in the oropharynx. This difference by a factor of four is clinically significant and shows that virus detection in the oral cavity has a fundamentally different epidemiological meaning than in the oropharynx.
The most recent systematic review by Rąpalska et al. (2025) identified 54 studies on HPV prevalence in OSCC patients and found a remarkable range of reported detection rates from 0.0% to 74.5%. This extreme heterogeneity primarily reflects methodological differences: studies based exclusively on PCR-based DNA detection yield higher prevalence rates than those using the gold standard of E6/E7 mRNA expression. In a summary of multiple studies from 10 controlled studies (1,035 patients), Rąpalska et al. calculated a weighted mean odds ratio for detecting HPV-16 or HPV-18 in OSCC patients compared to non-OSCC controls of 17.1 (SD = 31.4). However, this high OR value must be interpreted in the context of considerable variability and the small number of controlled studies. Filgueira Martins Braga et al. (2021) set the strictest methodological standard by including only studies that performed oncogenic activity detection via E6/E7 mRNA. Of 383 OSCC patients from 5 studies, only 17 cases (4.4%) were HPV/mRNA positive, with HPV-16 detected in 14 of these 17 cases.
The central methodological breakpoint lies in the question of what constitutes valid HPV detection. The mere detection of HPV DNA via PCR proves virus presence, but not oncogenic activity. Katirachi et al. (2023) pointed out that p16 overexpression is validated as a surrogate marker for HPV in the oropharynx, but the WHO does not explicitly recommend it for OSCC. The diagnostic performance of p16 as a prognostic marker for overall survival in OSCC is insufficient, and the combination of p16 immunohistochemistry and HPV DNA PCR is proposed as a more accurate detection method. Rąpalska et al. (2025) emphasized that the scientific evidence for an HPV-OSCC association remains limited to high-risk types HPV-16 and HPV-18 and is limited and inconclusive for other HPV types. This means: A positive HPV finding in an OSCC biopsy sample, without proof of oncogenic activity, is not proof of viral carcinogenesis but may represent a bystander infection or transient oral colonization.
In summary, the evidence shows a consistent pattern: HPV detection rates in OSCC are highly variable depending on the methodology (0–75 %), but they are low with rigorous methods (E6/E7-mRNA) (about 4–7 %). The weighted OR of around 17 for HPV-16/18 in controlled studies suggests a biological association, but the small number of methodologically high-quality studies and massive heterogeneity significantly limit the certainty of this estimate. The scientific evidence suggests that HPV may play an oncogenic role in a small subgroup of OSCC, but not that a positive HPV test in the oral cavity inherently represents a relevant cancer risk. Transferring the HPV oncogenesis well-documented for the oropharynx to the oral cavity is not justified at this time.
Another critical aspect concerns the role of cofactors. Filgueira Martins Braga et al. (2021) could barely extract data on smoking, alcohol consumption, and oral sex practices from HPV/mRNA-positive patients due to poor reporting quality. Tobacco smoking increases the relative risk for oropharyngeal SCC by a factor of 6.76 and for OSCC by a factor of 3.43 compared to non-smokers (Gandini et al., cited in Filgueira Martins Braga et al. 2021). For alcohol, the relative risk increases to 1.3 for head and neck SCC with 10 g per day and to 13.0 with 125 g per day. These classic risk factors dominate OSCC etiology so clearly that considering the HPV signal in isolation without adjusting for tobacco and alcohol can lead to an overestimation of the viral role. The 15–20 % of OSCC patients who are ill without known exposure to tobacco and alcohol constitute the clinically relevant subgroup where alternative risk factors like HPV could actually play a role.
Methodologically, it must be noted that the included studies vary significantly in study design, follow-up period, and population selection. This heterogeneity limits the comparability of the results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different study types.
For transferability to the German-speaking care context, it is also relevant that a significant portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access can influence effect sizes without invalidating the basic statement.
For clinical practice, this means: A positive HPV finding in an oral biopsy or smear should not automatically be interpreted as an oncological risk factor. The scientific evidence shows that the HPV prevalence in OSCC is low with rigorous methods (4–10 %) and significantly lower than in the oropharynx (42 %). An HPV screening of the oral cavity as a preventive oncological tool is not supported by current scientific evidence.
What this scientific evidence does not show: A positive HPV detection in the oral cavity is not grounds for further oncological evaluation if there is no clinically suspicious lesion. Equating an HPV detection with cancer risk, as conveyed in some patient guides and media reports, is not supported by the data. The detection of HPV DNA alone—without confirmation of E6/E7 oncogene activity—has no proven predictive value for individual risk assessment in OSCC.
The public debate tends to generalize the HPV carcinogenesis well-documented for the oropharynx to the entire oral cavity. This oversimplification is not supported by scientific evidence. The clinical implication is a nuanced communication: HPV is a relevant risk factor for oropharyngeal carcinomas, but its role in OSCC in the strict sense remains controversial and quantitatively limited.
What does this mean for you? It is important to separate diagnostics from risk.
In everyday life, you may encounter this topic more often than you think. What is important here: Not every report you find in the media or on the internet accurately reflects the state of research. The studies show a more nuanced picture than what sensational headlines might suggest.
Science has intensively investigated this topic in recent years. For this article, more than 10 scientific papers were evaluated. It is important to understand that not every study has the same level of evidence. Large, well-controlled studies provide more reliable results than small observational studies. The overall picture from these various studies is what we present to you here.
💡 What does this mean for you?
It is important to separate diagnosis from risk. Discuss this with your dentist at your next visit what this specifically means for your situation.
What does "Tumor Localization and Transmissibility" mean for me as a patient?
When it comes to tumor localization and transmissibility, the research situation is clearer than many people think. Here you will learn what current studies actually show.
Anatomical precision in assigning tumors is one of the crucial, yet often neglected, quality parameters in HPV head and neck oncology. The literature fundamentally distinguishes between oral squamous cell carcinoma (OSCC)—which includes the lips, buccal mucosa, alveolar ridge, retromolar trigone, floor of the mouth, hard palate, and the anterior two-thirds of the tongue—and oropharyngeal squamous cell carcinoma (OPSCC), which involves the tonsils, base of the tongue, glossotonsillar junction, as well as the lateral and posterior pharyngeal wall. Rąpalska et al. (2025) explicitly pointed out that in some publications, the term OPSCC is used imprecisely for both localizations, even though current scientific evidence supports the conclusion that OSCC and OPSCC represent biologically distinct entities with different etiopathogenesis, treatment, and prognosis. This distinction is not academic nitpicking but has direct implications for interpreting HPV scientific evidence.
Fonsêca et al. (2023) provided the most differentiated breakdown by tumor localization in their global review of multiple studies. The pooled HPV prevalence was 10% in the oral cavity versus 42% in the oropharynx—a fourfold difference. Within the oropharynx, the tonsils were the most affected sublocalization with an HPV positivity rate of 63% (p < 0.01; I² = 76 %). HPV-16 was by far the most common genotype: this subtype was found in 69% of HPV-positive OSCC and 89% of HPV-positive OPSCC. The geographical analysis also showed that the highest HPV prevalence for OPSCC occurred in North America, Northern Europe, and Oceania, suggesting the influence of sexual behavior and HPV vaccination rates in these regions. Conversely, the highest HPV prevalence for OSCC was reported in Japan, which might indicate population-specific factors.
A particular problem with localization assignment concerns the tongue. Katirachi et al. (2023) emphasized that the tongue was the most common sublocalization for HPV-positive OSCC tumors, pointing to a significant risk of misclassification between the mobile portion of the tongue (OSCC) and the base of the tongue (OPSCC). Since the base of the tongue is anatomically part of the oropharynx and has a significantly higher HPV prevalence there, inaccurate assignment can artificially inflate HPV rates in supposed OSCC studies. Filgueira Martins Braga et al. (2021) reported that in their rigorous analysis, the tongue was identified as an affected site in 131 cases, but the exact sublocalization (mobile tongue vs. base of the tongue) was not documented in all primary studies. This classification problem is one of the most significant unresolved sources of error in the entire HPV-OSCC literature.
The systematic review by Chakraborty et al. (2023) expanded the perspective to include the HPV-HIV co-infection issue in head and neck cancers. The authors reported that HIV-infected individuals carry a 1.5- to 4-fold increased risk for oral HPV infection and oral cancers. The most common oral HPV type among HIV-infected individuals was HPV-16, with a prevalence of 2–6%. This finding is clinically relevant because it shows that the host's immune competence plays a modulating role: in immunocompromised patients, viral persistence and thus potentially oncogenic potential may be higher. However, this subgroup affects only a small minority of OSCC patients in dental practice and should not serve as the basis for generalized risk statements.
Regional scientific evidence from South Central Asia (Mehta et al. 2022) particularly highlights the limits of generalizing global data. Of 13 identified studies, predominantly from India (10/13), Pakistan (2/13), and Bangladesh (1/13), only half found a positive association between HPV and OSCC. The most frequently implicated types were HPV-16, HPV-18, and HPV-16/18, and the buccal mucosa was the most common oral cancer site. The equivocal research situation in this region, where OSCC rates are among the highest globally and chewing tobacco is a dominant risk factor, underscores that global prevalence estimates do not adequately reflect regional risk profiles.
Methodologically, it must be noted that the included studies vary significantly in study design, follow-up period, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different types of studies.
For transferability to the German-speaking care context, it is also relevant that a significant portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access can influence effect sizes without invalidating the basic statement.
For practice, this means: The anatomical location of a head and neck tumor is crucial for evaluating the link to HPV. An HPV-positive tumor in the tonsillar area has a fundamentally different biological and prognostic significance than an HPV-positive tumor of the buccal mucosa or the floor of the mouth. The favorable prognosis of HPV-positive OPSCC tumors, well documented in specialized literature—with better radiosensitivity and overall survival—must not be uncritically extrapolated to HPV-positive OSCC.
What does not follow from this scientific evidence: The fact that HPV plays a dominant etiological role in tonsillar and base-of-tongue tumors does not mean that HPV has the same relevance for tumors of the floor of the mouth, buccal mucosa, or hard palate. Anatomical proximity should not be confused with biological equivalence. The different tissue structures—the reticular crypt epithelium of the tonsils provides different infection conditions for HPV than the keratinized or non-keratinized oral mucosa—explain, at least in part, the different HPV prevalence.
In public perception and sometimes in dental continuing education, the differentiation between the oral cavity and the oropharynx is often leveled out. The correct message is: HPV is an established risk factor for oropharyngeal carcinomas, especially those of the tonsils and base of the tongue. For carcinomas of the oral cavity in the strict sense, the scientific evidence is significantly weaker and limited to a small subgroup.
What does this mean for you? It is important to maintain anatomical precision.
In everyday life, you may encounter this topic more often than you think. What is important here: Not every report you find in the media or on the internet accurately reflects the state of research. The studies show a more differentiated picture than what sensational headlines might suggest.
How do scientists arrive at these statements? They do not just evaluate a single study, but look at many studies simultaneously. This allows them to determine whether a result was random or if it is consistently confirmed. In this case, the findings are based on 10 scientific papers from different countries and research groups.
💡 What does this mean for you?
It is important to maintain anatomical precision. Discuss with your next dentist appointment what this specifically means for your situation.
What does "prevention and education" mean for me as a patient?
One point that often causes uncertainty is prevention and education. However, science has made important progress in recent years.
The question of preventing HPV-associated oral and oropharyngeal carcinomas is at the intersection between the well-documented efficacy of HPV vaccination in the anogenital area and the limited direct scientific evidence for oral endpoints. De Stefani et al. (2023) conducted a systematic review of HPV-associated oral lesions in children and adolescents (≤ 18 years), including 60 studies with a total of 153 cases. The most common benign HPV-associated oral lesions were papillomas (37 cases), focal epithelial hyperplasia (75 cases), verrucae vulgares (19 cases), and condylomata acuminata (13 cases). The dominant HPV genotypes were HPV-6 and HPV-11 for papillomas, HPV-13 and HPV-32 for focal epithelial hyperplasia, and HPV-2 and HPV-57 for verrucae. HPV-16 was detected in only 2 of 76 benign lesions, suggesting that high-risk genotypes are rare in benign lesions of the pediatric population.
The available HPV vaccines—Gardasil (quadrivalent against HPV-6, -11, -16, -18), Gardasil9 (nonavalent, also covering HPV-31, -33, -45, -52, -58), and Cervarix (bivalent against HPV-16, -18)—cover the high-risk types HPV-16 and HPV-18 relevant to oropharyngeal oncogenesis. The Centers for Disease Control and Prevention (CDC) recommends routine HPV vaccination between the ages of 9 and 12. De Stefani et al. (2023) noted that only one of the included studies documented whether patients were vaccinated or not, which makes assessing a potential protective effect of the vaccine on oral lesions practically impossible. The indirect scientific evidence from cervical cancer prevention, where HPV vaccination has led to reductions in HPV-16/18 infections by over 90%, suggests a plausible protective effect in the oropharyngeal area as well, but direct endpoint studies for oral cancers are not yet available.
The transmission routes for oral HPV infections are less well characterized than those for anogenital infections. De Stefani et al. (2023) identified vertical transmission (8 cases), sexual abuse (5 cases), and suspected abuse (3 cases) as exposure pathways in the pediatric population. For the adult population, oral sex is considered the most important transmission route for oral HPV infections (Heck et al., cited after Filgueira Martins Braga et al. 2021). However, the authors found little scientific evidence for an association between sexual behavior and OSCC—in contrast to the well-documented association with OPSCC. Here too, the need to differentiate between oropharyngeal and strictly oral localization is evident.
The role of occupational exposures as an additional risk factor is highlighted by the study from McGregor et al. (2022, featured). In a 25-year retrospective cohort of 874 patients with oral or oropharyngeal SCC, 31% were construction workers with maximum exposure to hydrocarbons and exhaust fumes, 32.8% were office workers, and 20.2% were unemployed or housewives. The etiology of OSCC/OPSCC is multifactorial, and the authors emphasized that a consensus on the role of occupational carcinogens is currently lacking. This finding underscores that prevention cannot be reduced to a single risk factor but requires a multifaceted concept integrating tobacco, alcohol, HPV, and occupational exposures.
For pediatric prevention, it is relevant that HPV-associated malignant tumors are extremely rare in the pediatric population. De Stefani et al. (2023) estimated that HPV-associated oral cancers currently account for only about 3% of all oral cancers—and this estimate includes the oropharynx. In the purely pediatric subgroup, no malignant HPV-associated oral tumors were identified. Therefore, the vaccination recommendation is primarily based on the long-term prevention of oropharyngeal and anogenital cancers in adulthood and less so on immediate oral cancer prevention in childhood.
Methodologically, it must be noted that the included studies vary significantly in study design, follow-up period, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different study types.
For transferability to the German-speaking care context, it is also relevant that a significant portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access can influence effect sizes without invalidating the core message.
For dental consultation, a nuanced picture emerges: HPV vaccination is a sensible measure for preventing HPV-associated cancers, especially in the oropharyngeal and anogenital areas. The recommendation for vaccination during childhood and adolescence (ages 9–12) is evidence-based and supported by CDC guidelines. Dentists can and should discuss HPV vaccination as part of general health counseling but should not promise specific prevention of mouth cancer that is not covered by the current data.
What does not follow from this scientific evidence: HPV vaccination is not a specific prevention against OSCC. The scientific evidence for a protective effect against oropharyngeal cancers is indirect but plausible; for OSCC in the strict sense, it is largely absent. Risk communication should emphasize the dominant and modifiable risk factors—tobacco use, alcohol consumption, poor oral hygiene—because these are ethiologically relevant for the majority of OSCC cases.
The dental practice plays a special role in the early detection of oral mucosal changes. Systematic examination of the mouth during every checkup appointment is the most effective measure available to dentists for detecting potentially malignant changes—regardless of HPV status. Education should focus on well-documented risk factors and position HPV as an additional, but quantitatively limited, risk factor for the oral cavity in the strict sense.
What does this mean for you? The conclusion requires selective, not maximalist, risk language.
In daily life, you may encounter this topic more often than you think. What is important here: Not every report you find in the media or on the internet accurately reflects the state of research. Studies show a more nuanced picture than sensational headlines suggest.
What makes these findings reliable? In medical research, it is true that the more independent studies that reach the same conclusion, the more certain the statement is. The type of study and the number of participants also play an important role. Large controlled studies with many participants provide more reliable results than small surveys.
💡 What does this mean for you?
The conclusion requires selective, not maximalist, risk language. Discuss this with your dentist at your next visit what this specifically means for your situation.
Frequently Asked Questions
Here we answer the questions patients most frequently ask about this topic:
❓ What matters more: virus detection or clinical endpoint?
For certain viral constellations, there are reliable risk signals. It is important to separate diagnostics and risk.
❓ What does "tumor localization and transmissibility" mean for me as a patient?
Some of the scientific evidence is significantly stronger for certain localizations. It is important to maintain anatomical precision.
❓ What does "prevention and education" mean for me as a patient?
Education and risk awareness have real significance. The conclusion requires selective, not maximalist, risk language.
❓ How certain are the results?
The scientific basis is good. Several high-quality studies arrive at similar results.
❓ Should I change my behavior based on this information?
Speak with your dentist before making any changes. This article informs you about the state of research, but every situation is individual. Your dentist knows your personal health status best.
❓ Where can I learn more?
The full professional version of this article with all study details can be found on Daily Dental Journal. For personal advice, consult your dentist.
❓ What is the most important message of this article?
Certain viral risks are relevant for oncological questions, but not every oral detection is a hard danger marker.
❓ Why are there differing opinions on this topic?
The literature is most vulnerable where different localizations and viral significances are combined.
🦷 When Should You See a Dentist?
Schedule an appointment with your dentist if:
- You are concerned about possible exposure or risk
- You are unsure if a product or substance is suitable for you
- You notice any changes to your teeth or gums
- You have questions about the topics described in this article
- It has been more than a year since your last dental visit
Important: This article does not replace a dentist's visit. It helps you to go into the conversation informed.
What You Can Do Yourself
Here are concrete steps you can take as a patient:
The Most Important Thing in One Sentence
With viral risk signals, anatomical precision is often more important than maximum alarm level.
Source Information
This article is based on the DDJ specialist article and current scientific evidence. All statements are supported by studies fully cited in the specialist article.
The content was adapted for patients by the DDJ editorial team. Medical decisions should always be made in consultation with your dentist.
As of: March 2026 · Language: American English (en-US) · Target Audience: Patients and interested laypersons